Renal Cell Carcinoma: A Flourishing Landscape

While reflecting on an episode involving an assertive patient, Sandy Srinivas, MD, appraises the increasingly multifaceted landscape of renal cell carcinoma therapy, from the relatively sparse scene of a decade ago in which only a handful of tyrosine kinase inhibitors and one interleukin-2 inhibitor were available, to the current setting with exponentially more options, including the combinations of cabozantinib with nivolumab, axitinib with pembrolizumab, and lenvatinib with pembrolizumab.

Medscape © 2022 WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Renal Cell Carcinoma: A Flourishing Landscape - Medscape - Jan 25, 2022.